TABLE 2. Basal values of mean arterial pressure, renal function and electrolyte excretion.
Group name | MAP (mmHg) | GFR (ml/min per g) | RBF (ml/min per g) | UNaV (μmol/min per g) | FENa (%) | V (μl/min per g) |
---|---|---|---|---|---|---|
I3C-induced + untreated | 162 ± 3@ | 1.45 ± 0.27* | 6.03 ± 0.34# | 1.48 ± 0.25@ | 1.32 ± 0.22@ | 13.51 ± 1.48@ |
I3C-induced + c-AUCB | 134 ± 3* | 1.99 ± 0.19* | 9.24 ± 0.62@ | 1.91 ± 0.27@ | 2.04 ± 0.29@ | 12.18 ± 1.81@ |
I3C-induced + L-NAME | 163 ± 4@ | 0.69 ± 0.11 | 2.61 ± 0.17 | 0.29 ± 0.09* | 0.25 ± 0.07* | 3.82 ± 0.34* |
I3C-induced + L-NAME + c-AUCB | 161 ± 3@ | 0.61 ± 0.14 | 2.09 ± 0.24 | 0.35 ± 0.06* | 0.33 ± 0.04* | 4.11 ± 0.29* |
I3C-induced + L-NAME + RAS blockade | 109 ± 4 | 0.74 ± 0.14 | 3.69 ± 0.23* | 0.66 ± 0.05# | 0.71 ± 0.06# | 6.52 ± 0.27 |
Noninduced + untreated | 111 ± 3 | 1.89 ± 0.17* | 8.02 ± 0.41# | 0.43 ± 0.06* | 0.39 ± 0.08* | 4.98 ± 0.36* |
Noninduced + c-AUCB | 112 ± 3 | 2.21 ± 0.21* | 7.22 ± 0.53# | 0.47 ± 0.05* | 0.44 ± 0.09* | 4.66 ± 0.42* |
Noninduced + L-NAME | 136 ± 4* | 0.71 ± 0.19 | 2.37 ± 0.16 | 0.09 ± 0.02 | 0.11 ± 0.03 | 2.54 ± 0.22 |
Noninduced + L-NAME + c-AUCB | 135 ± 5* | 0.65 ± 0.11 | 1.99 ± 0.21 | 0.14 ± 0.04 | 0.16 ± 0.05 | 2.63 ± 0.21 |
Noninduced + L-NAME + RAS blockade | 110 ± 4 | 0.73 ± 0.14 | 3.71 ± 0.28* | 0.29 ± 0.04* | 0.33 ± 0.06* | 3.61 ± 0.18* |
c-AUCB, treatment with the soluble epoxide hydrolase inhibitor; FENa, fractional sodium excretion; GFR, glomerular filtration rate; I3C, administration of indole-3-carbinol; L-NAME, treatment with nitric oxide synthase inhibitor; MAP, mean arterial pressure; RAS, renin-angiotensin system; RBF, renal blood flow; UNaV, absolute sodium excretion; V, urine flow.
P < 0.05 vs. unmarked values.
P < 0.05 vs. marked values.
P < 0.05 vs. all values.